Fox Run Management, L.L.C. Janux Therapeutics, Inc. Transaction History
Fox Run Management, L.L.C.
- $588 Million
- Q3 2025
A detailed history of Fox Run Management, L.L.C. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 24,294 shares of JANX stock, worth $711,328. This represents 0.1% of its overall portfolio holdings.
Number of Shares
24,294Holding current value
$711,328% of portfolio
0.1%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
182Shares Held
54.8MCall Options Held
598KPut Options Held
212K-
Ra Capital Management, L.P. Boston, MA11.2MShares$328 Million4.7% of portfolio
-
Janus Henderson Group PLC London, X04.7MShares$138 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$85.5 Million2.3% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.78MShares$81.3 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$70.8 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.22B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...